

POSTER PRESENTATION

Open Access

P070. A 2-year prospective evaluation study on onabotulinumtoxinA 155 U in chronic migraine

Andrea Negro*, Lidia D'Alonzo, Noemi Lala, Paolo Martelletti

From Abstracts from the 1st Joint ANIRCEF-SISC Congress
Rome, Italy. 29-31 October 2015

Background

OnabotulinumtoxinA (Botox®) is the first and so far the only treatment to receive a specific license for prevention of chronic migraine (CM). In our Headache Clinic the therapy with onabotulinumtoxinA is routinely administered to CM patients on a daily basis since 2001. Preventive treatment with onabotulinumtoxinA was offered to all patients that were 1) adults; 2) fulfilling the ICHD-II criteria for CM with or without analgesic overuse; and 3) with contraindications or lack of efficacy or tolerability to other preventive drugs.

Exclusion criteria were coexistent neuromuscular disorders, psychiatric diseases considered incompatible with this kind of treatment, pregnancy and breast-feeding.

Objectives

To prospectively evaluate the variations in terms of headache days, migraine days, acute pain medication intake days through a period of 24 months in comparison to a one-month baseline period before starting the therapy.

Methods

Among all the patients that from 2011 to 2012 underwent treatment with onabotulinumtoxinA we randomly

selected 100 CM patients (F 88 / M 12; mean age 43.2, range 18-80 years; 96% drugs overusers) that were able to fill in diaries without any lack of information for a period of 2 years. OnabotulinumtoxinA 155 U was injected in 31 sites following the PREEMPT "fixed sites/fixed doses" injection paradigm every three months (\pm one week) [1]. Patients with criteria for medication-overuse headache underwent withdrawal and detoxification therapeutic regimen before starting the treatment. Patients were not allowed to continue preventive oral medication during treatment with onabotulinumtoxinA.

Results

The efficacy results for each timeline are reported in Table 1. The reduction in terms of headache and migraine days, acute medication intake days and HIT-6 score increases strongly from the first injection to the fourth, and remains stable until the last injection at 24 months.

Conclusions

Our results support findings of PREEMPT study in a large cohort of patients and are representative of the patients observed in a tertiary headache centre.

Written informed consent to publish was obtained from the patient(s).

Table 1. Efficacy of onabotulinumtoxinA 155 U

	baseline	3 m	6 m	9 m	12 m	15 m	18 m	21 m	24 m
Headache days	22.3	-5.9	-9.4	-10.7	-12.9	-13.2	-13.6	-14.3	-15
Migraine days	21.4	-5.6	-8.4	-9.5	-12.3	-13.1	-13.5	-14.1	-14.6
Acute pain medication intake days	20.8	-6.6	-9	-9.8	-12.1	-12.6	-13.2	-14.8	-15.6
HIT-6 score	69.4	-	-5.1	-	-10.9	-	-14	-	-17.4

* Correspondence: andrea.negro@uniroma1.it
Department of Clinical and Molecular Medicine, Sapienza University of Rome, Sant'Andrea Hospital, Rome, Italy

Published: 28 September 2015

Reference

1. Blumenfeld A, Silberstein SD, Dodick DW, Aurora SK, Turkel CC, Binder WJ: Method of injection of onabotulinumtoxinA for chronic migraine: a safe, well-tolerated, and effective treatment paradigm based on the PREEMPT clinical program. *Headache* 2010, **50**(9):1406-1418.

doi:10.1186/1129-2377-16-S1-A137

Cite this article as: Negro et al.: P070. A 2-year prospective evaluation study on onabotulinumtoxinA 155 U in chronic migraine. *The Journal of Headache and Pain* 2015 **16**(Suppl 1):A137.

Submit your manuscript to a SpringerOpen[®] journal and benefit from:

- Convenient online submission
- Rigorous peer review
- Immediate publication on acceptance
- Open access: articles freely available online
- High visibility within the field
- Retaining the copyright to your article

Submit your next manuscript at ► springeropen.com
